Bill Gates sees the main importance for India, AstraZeneca US studies are keeping Covid-19 vaccines Last Updates
The WHO welcomed the decision by AstraZeneca to suspend its vaccine research, while the official Chinese reports that in November 2020 vaccines will be made publicly available.
The quest to develop a new coronavirus vaccine continues even as the pandemic is catastrophic across the world. Though more than 4.9 million cases of the disease have been reported by India so far, according to EU Health Ministers reports, over 29 million cases per world-meter have been reported worldwide to date.
As many potential vaccines are being tested worldwide, and people hope for the breakthrough, on Tuesday the US businessman and Microsoft partner Bill Gates called India a leading vaccine manufacturer.
Meanwhile, the CEO of the Pune-based Serum Institute of India (SII) Adar Poonawalla expressed apprehension that no appropriate worldwide vaccine was to take place before the end of 2024.
Recent advances in vaccine studies of Covid-19:
- On Tuesday, Microsoft co-founder Bill Gates expressed hope that Covid-19 will be introduced in India in a large-scale vaccine next year. "We all want a vaccine to be published in India as soon as we know it to be extremely efficient and safe.
- Poonawalla whose SII is in collaboration with five Foreign vaccine developers – including AstraZeneca and Novovax – said that, if a two-dose vaccine is a Covid-19, the world would need about 15 trillion doses.
- AstraZeneca's Covid-19 vaccine tests in the United States are still under way until at least mid-week, pending an inquiry by the United States into a significant side effect in Britain.
In the meantime, the World Health Organization (WHO) welcomed AstraZeneca's decision to suspend its Covid-19 vaccine tests, stating that safety was indeed critical, critical and thoroughly investigated by AstraZeneca.
- The official from China announced that in November 2020 the vaccine could be used by the public in the region. China currently has at least three vaccines available for urgent use at the final stage of the clinical trials.
- More than 300 volunteers have been inoculated with 14 percent recorded "minor concern" in post-registration tests with the Russian vaccine CovidD-19 dubbed Sputnik V.